CORRECT: Arcontech profit and sales fall; Kromek profit tops forecast
15th Sep 2026 15:56
(Corrects the financial 2026 gross margin figure for Fusion Antibodies PLC to 58.3%.) Read More
| Price | 6.00p on 08-10-2026 at 07:50:00 |
|---|---|
| Change | -0.10p -1.64% |
| Buy | 6.10p |
| Sell | 5.90p |
| Last Trade: | Buy 16,381.00 at 6.08p |
| Day's Volume: | 149,862 |
| Last Close: | 6.10p |
| Open: | 6.00p |
| ISIN: | GB00BD7V5D43 |
| Day's Range | 6.00p - 6.00p |
| 52wk Range: | 6.00p - 12.80p |
| Market Capitalisation: | £39.32m |
| VWAP: | 6.046471p |
| Shares in Issue: | 655.30m |
Sector: Medical Services
Listed In: FTSE AIM All-Share,
Kromek (KMK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 16,381 | 6.08p | Ordinary |
08:48:03 - 08-Oct-26 |
| Sell* | 8,502 | 5.951p | Ordinary |
08:43:45 - 08-Oct-26 |
| Buy* | 327 | 6.10p | SI Trade |
08:36:29 - 08-Oct-26 |
| Buy* | 86 | 6.10p | SI Trade |
08:36:29 - 08-Oct-26 |
| Buy* | 38 | 6.10p | SI Trade |
08:36:29 - 08-Oct-26 |
| Sell* | 114 | 5.90p | Ordinary |
08:33:09 - 08-Oct-26 |
| Sell* | 30,510 | 5.951p | Ordinary |
08:28:30 - 08-Oct-26 |
| Buy* | 20 | 6.10p | SI Trade |
08:08:43 - 08-Oct-26 |
| Buy* | 81 | 6.10p | SI Trade |
08:08:43 - 08-Oct-26 |
| Buy* | 20 | 6.10p | SI Trade |
08:08:43 - 08-Oct-26 |
Kromek (KMK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 2nd Oct 2026 7:00 am | RNS | Notice of AGM, Directorate Changes & Annual Report |
| 16th Sep 2026 3:57 pm | RNS-R | Notice of Investor Webinar |
| 15th Sep 2026 11:36 am | RNS | Director Share Purchase |
| 14th Sep 2026 12:38 pm | RNS | Director Share Purchase |
| 14th Sep 2026 7:00 am | RNS | Final Results |
| 6th Aug 2026 7:00 am | RNS | Delivery of Third Milestone and Grant of Options |
| 3rd Aug 2026 7:00 am | RNS | Director Share Purchase |
| 4th Jun 2026 7:00 am | RNS | Grant of Long-Term Incentives |
| 2nd Jun 2026 7:00 am | RNS-R | Launch of new interactive investor hub |
| 1st Jun 2026 7:00 am | RNS | PDMR/Director Shareholding, Issue of Equity & TVR |